CA3077359A1 - Compositions and methods for modulating hair growth - Google Patents

Compositions and methods for modulating hair growth Download PDF

Info

Publication number
CA3077359A1
CA3077359A1 CA3077359A CA3077359A CA3077359A1 CA 3077359 A1 CA3077359 A1 CA 3077359A1 CA 3077359 A CA3077359 A CA 3077359A CA 3077359 A CA3077359 A CA 3077359A CA 3077359 A1 CA3077359 A1 CA 3077359A1
Authority
CA
Canada
Prior art keywords
acid
electron transport
transport chain
inhibitor
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3077359A
Other languages
English (en)
French (fr)
Inventor
Matilde Miranda
Aimee FLORES
William E. Lowry
Heather R. Christofk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA3077359A1 publication Critical patent/CA3077359A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)
CA3077359A 2017-09-29 2018-09-28 Compositions and methods for modulating hair growth Abandoned CA3077359A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566031P 2017-09-29 2017-09-29
US62/566,031 2017-09-29
PCT/US2018/053351 WO2019067860A1 (en) 2017-09-29 2018-09-28 COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH

Publications (1)

Publication Number Publication Date
CA3077359A1 true CA3077359A1 (en) 2019-04-04

Family

ID=65903207

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3077359A Abandoned CA3077359A1 (en) 2017-09-29 2018-09-28 Compositions and methods for modulating hair growth

Country Status (16)

Country Link
US (1) US20200253917A1 (enExample)
EP (1) EP3687528A4 (enExample)
JP (1) JP2020536048A (enExample)
KR (1) KR20200062242A (enExample)
CN (1) CN111295188A (enExample)
AU (1) AU2018339064A1 (enExample)
BR (1) BR112020003349A2 (enExample)
CA (1) CA3077359A1 (enExample)
CL (1) CL2020000676A1 (enExample)
EA (1) EA202090855A1 (enExample)
IL (1) IL272827A (enExample)
MX (1) MX2020002389A (enExample)
PE (1) PE20210464A1 (enExample)
PH (1) PH12020500300A1 (enExample)
SG (2) SG10202109849SA (enExample)
WO (1) WO2019067860A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019015552A2 (pt) 2017-02-24 2020-03-17 The Regents Of The University Of California Composições e métodos para promover crescimento capilar com os inibidores de mpc1
MX2019015475A (es) 2017-06-30 2020-02-19 Univ California Composiciones y metodos para modular el crecimiento del cabello.
KR102561912B1 (ko) * 2021-04-09 2023-07-31 차의과학대학교 산학협력단 세팔로틴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 탈모방지 또는 발모촉진용 조성물
CN113694063A (zh) * 2021-08-31 2021-11-26 佛山市第一人民医院（中山大学附属佛山医院） 一种组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014221D0 (en) * 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
AU3982601A (en) * 2000-02-23 2001-09-03 Orentreich Foundation For The Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
EP1796660B1 (en) * 2004-09-17 2016-11-23 BioMAS Ltd. Use of ammonium trichloro(dioxyethylene-o,o')tellurate (as101) for the inhibition of interleukin-1beta-converting enzyme
AU2006339311A1 (en) * 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8343962B2 (en) * 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
US9308181B2 (en) * 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US8563500B2 (en) * 2007-09-05 2013-10-22 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
EP3178465A1 (en) * 2010-12-06 2017-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
CN106880693A (zh) * 2017-03-22 2017-06-23 广州国草夏方生物科技有限公司 一种治疗脂溢性脱发的生发液组合物及其制备方法

Also Published As

Publication number Publication date
CN111295188A (zh) 2020-06-16
AU2018339064A1 (en) 2020-02-27
PE20210464A1 (es) 2021-03-08
EP3687528A4 (en) 2021-07-21
SG11202001516QA (en) 2020-03-30
IL272827A (en) 2020-04-30
SG10202109849SA (en) 2021-10-28
CL2020000676A1 (es) 2020-09-25
US20200253917A1 (en) 2020-08-13
EA202090855A1 (ru) 2020-06-26
JP2020536048A (ja) 2020-12-10
PH12020500300A1 (en) 2020-11-09
WO2019067860A1 (en) 2019-04-04
EP3687528A1 (en) 2020-08-05
KR20200062242A (ko) 2020-06-03
BR112020003349A2 (pt) 2020-08-18
MX2020002389A (es) 2020-10-01

Similar Documents

Publication Publication Date Title
US20230190736A1 (en) Small molecule therapeutics for the treatment of viral infections
US20200253917A1 (en) Compositions and methods for modulating hair growth
US20110311478A1 (en) Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium
JP2018117625A (ja) 食欲不振制御化合物の組成物および使用方法
CN105943530B (zh) 铁死亡抑制剂在制备治疗铁过载疾病的药物中的应用
US20230040125A1 (en) Targeting the intrinsic apoptotic machinery in glioblastoma
EP3366288B1 (en) Lithium ascorbate exhibiting anti-stress, anxiolytic and anti-depression activity
HK40026046A (en) Compositions and methods for modulating hair growth
CN111032035A (zh) 用于替司他赛和卡培他滨的给药方案
US20070293485A1 (en) Drug administration methods
KR20250044649A (ko) X-ald 치료를 위한 갑상선 베타-작용제 투여 요법
WO2020242910A1 (en) Compositions and methods for treating cancer
WO2025166338A2 (en) Systemic mpc inhibition to reverse signs of aging
US20160113955A1 (en) Compositions And Methods For Immunotherapy
EP4580650A1 (en) Thiostrepton dosing regimens
WO2023239842A1 (en) Beta carbolines as topical anti-inflammatory agents for application to mucous membranes
WO2025188928A1 (en) Administration of low-dose thiostrepton for treating cancer
WO2024035876A2 (en) Compositions and methods of treating cancer
WO2025117739A1 (en) Compositions and methods for treating cancer
RU2557889C1 (ru) Средство для лечения кокцидиозов у птиц и животных
HK40089161A (zh) 烟醯胺腺嘌呤二核苷酸(nad)浓度上升剂
US20190388450A1 (en) Compositions And Methods For Immunotherapy
HK40029016A (en) Dosing schedule for tesetaxel and capecitabine
HK1196547A (en) Usage of compound for preparing composition for treating, modifying and managing bone cancer pain

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240328